Canadian drug listing: Optimizing time to reimbursement
By Innomar Strategies
Did you know it can take up to two years post-Health Canada approval for medications to be paid for by public drug programs? This can delay patient access to your therapies. In this video, Beth Koster, Director, Health Economics & Outcomes Research (HEOR), shares insightful tips, including the importance of having knowledgeable guidance to navigate the system effectively.
The contents of this piece contain marketing statements and do not include business or legal advice.
Transcript of 'Canadian drug listing: Optimizing time to reimbursement'
How can you optimize the time to drug listing in Canada?
The market access and pricing landscape in Canada is very complex, involves a lot of stakeholders, and takes a lot of time. Many companies are surprised that it could take up to two years after Health Canada approval for the medication to be paid for by our public drug programs. So, this obviously creates a gap for patients while they're waiting for their therapies to come to market. Often companies are asking us how they can shorten that time or optimize that time to reimbursement in Canada. Some of the best practices to optimize that time to listing would be to have a solid strategy in place, make sure you start early and engage proactively, continue to collect data because you never know when you're going to need it. It's also helpful if you have somebody that knows the landscape and knows the players, and it can help you navigate the complex system in Canada.
